KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Total Debt (2016 - 2025)

Historic Total Debt for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to -$20.1 billion.

  • Gsk's Total Debt fell 1676.43% to -$20.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.1 billion, marking a year-over-year decrease of 1676.43%. This contributed to the annual value of -$15.7 billion for FY2024, which is 17008.75% down from last year.
  • Per Gsk's latest filing, its Total Debt stood at -$20.1 billion for Q3 2025, which was down 1676.43% from -$20.4 billion recorded in Q2 2025.
  • Gsk's 5-year Total Debt high stood at $32.6 billion for Q4 2021, and its period low was -$31.8 billion during Q1 2021.
  • Over the past 5 years, Gsk's median Total Debt value was -$20.1 billion (recorded in 2025), while the average stood at -$13.6 billion.
  • As far as peak fluctuations go, Gsk's Total Debt skyrocketed by 6046.69% in 2022, and later plummeted by 17052.55% in 2024.
  • Over the past 5 years, Gsk's Total Debt (Quarter) stood at $32.6 billion in 2021, then dropped by 24.54% to $24.6 billion in 2022, then fell by 9.15% to $22.4 billion in 2023, then tumbled by 170.53% to -$15.8 billion in 2024, then dropped by 27.4% to -$20.1 billion in 2025.
  • Its last three reported values are -$20.1 billion in Q3 2025, -$20.4 billion for Q2 2025, and -$20.7 billion during Q1 2025.